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Monoacylglycerol lipase (MAGL) is a principal degra-
dative enzyme for the endocannabinoid 2-arachido-
noylglycerol (2-AG). We recently reported a piperidine
carbamate, JZL184, that inhibits MAGL with high
potency and selectivity. Here, we describe a compre-
hensive mechanistic characterization of JZL184. We
provide evidence that JZL184 irreversibly inhibits
MAGL via carbamoylation of the enzyme’s serine
nucleophile. Functional proteomic analysis of mice
treated with JZL184 revealed that this inhibitor main-
tains good selectivity for MAGL across a wide range
of central and peripheral tissues. Interestingly,
MAGL blockade produced marked, tissue-specific
differences in monoglyceride metabolism, with brain
showing the most dramatic elevations in 2-AG and
peripheral tissues often showing greater changes in
other monoglycerides. Collectively, these studies
indicate that MAGL exerts tissue-dependent control
over endocannabinoid and monoglyceride metabo-
lism and designate JZL184 as a selective tool to char-
acterize the functions of MAGL in vivo.
INTRODUCTION
Monoacylglycerol lipase (MAGL) is a 33 kDa, peripherally associ-
ated membrane enzyme of the serine hydrolase superfamily that
catalyzes the hydrolysis ofmonoacylglycerols (MAGs) to free fatty
acid and glycerol (Karlsson et al., 1997; Tornqvist and Belfrage,
1976). MAGL contains the classical GXSXG consensus sequence
common tomost serine hydrolases and is predicted by sequence
homology to have an a/b-hydrolase fold. The catalytic triad has
been identified as Ser122, His269, and Asp239 (Karlsson et al.,
1997). ThoughMAGLcanhydrolyze1(3)-and2-MAGsequally effi-
ciently, it has an exquisite substrate preference for MAGs over tri-
acylglycerols and diacylglycerols (Fredrikson et al., 1986; Tornqv-
ist and Belfrage, 1976). Beyond its initially described contribution
to lipolysis in adipose tissue, MAGL has also been proposed
to degrade the endogenous cannabinoid (endocannabinoid)
2-arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura
et al., 1995) in the nervous system (Dinh et al., 2002). 2-AG, along
with a second endocannabinoid anandamide (AEA) (Devane et al.,
1992), are signaling lipids that activate the cannabinoid receptors744 Chemistry & Biology 16, 744–753, July 31, 2009 ª2009 ElsevieCB1 (Matsuda et al., 1990) and CB2 (Munro et al., 1993), two
G-protein-coupled receptors that alsomediate the neurobehavio-
ral and immunosuppressive effects of the psychoactive compo-
nent of marijuana, D9-tetrahydocannabinol (Ledent et al., 1999;
Mackie, 2006; Zimmer et al., 1999). Endocannabinoids have
been implicated in the regulation of a number of (patho)physiolog-
ical processes that reflect functions in both the nervous system
(e.g., pain, anxiety, cognition) and peripheral tissues (e.g., dyslipi-
demia, inflammation, fertility) (DiMarzoetal., 2007;Mackie, 2006).
Endocannabinoid signaling is terminated by enzymatic hydro-
lysis, a process that, for AEA, occurs by the action of fatty acid
amide hydrolase (FAAH) (Cravatt et al., 1996, 2001). Although
several enzymes have been implicated in the hydrolysis of
2-AG, we and others have provided evidence that MAGL is the
principal 2-AG hydrolase in rodent brain (Blankman et al., 2007;
Dinh et al., 2002, 2004; Nomura et al., 2008a, 2008b). To investi-
gate the role that MAGL plays in endocannabinoid metabolism
andsignaling in vivo,we recently describedapotent andselective
inhibitor of this enzyme termed JZL184 (Long et al., 2009) that,
upon administration to mice, decreased brain MAG hydrolysis
activity by up to 85%anddramatically elevatedbrain 2-AG levels.
These biochemical and metabolic changes were accompanied
by several CB1-dependent behavioral phenotypes, including
hypomotility, hypothermia, and analgesia. Key to the develop-
ment of JZL184 was the implementation of competitive activity-
based protein profiling (ABPP) screens (Leung et al., 2003; Li
et al., 2007) to direct the concurrent optimization of inhibitor
potency and selectivity. Here, we extend this initial study by pre-
senting a detailed mechanistic characterization of JZL184. We
provide evidence that JZL184 inhibits MAGL by carbamoylation
of the enzyme’s active site serine nucleophile. We also demon-
strate that JZL184 can be used to globally inactivate MAGL in
both central and peripheral tissues, where the inhibitor maintains
good selectivity, showing only a handful of off-targets in a select
subset of tissues. Interestingly, we observed marked tissue-
specific differences in the accumulation of 2-AG and other MAG
species uponMAGL inhibition, suggesting that endocannabinoid
tone and its regulation by MAGL vary across individual organs.
RESULTS
JZL184 Inhibits MAGL by Irreversible Active-Site
Carbamoylation
Carbamate inhibitors typically inactivate serine hydrolases
by irreversible (or slowly reversible) covalent modificationr Ltd All rights reserved
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MAGL Function in Endocannabinoid MetabolismFigure 1. Mechanism of JZL184 Inhibition
of MAGL
(A) Proposed mechanism for covalent inactivation
of MAGL by JZL184 involving carbamoylation of
the enzyme’s catalytic serine nucleophile (Ser122).
(B) Extracted ion chromatograms (EIC) of the
unmodified (top) and JZL184-modified (bottom)
MAGL active site tryptic peptide (amino acids
110–160). Recombinant, purified human MAGL
was treated with DMSO (black trace) or JZL184
(200 mM, red trace). The mass window for each
EIC, the detected high-resolution mass for each
peak, and the charge state for each tryptic
peptide are indicated.
(C) MS/MS spectra generated by the unmodified
and modified active site peptides. Diagnostic y
and b ions are identified. All ions are in the 1+
charge state unless otherwise indicated.
(D) JZL184-treated MAGL was incubated at room
temperature in 50 mM Tris (pH 8.0), and the
activity remaining as a percentage of control reac-
tions (treated with DMSO) was measured by 2-AG
hydrolysis assays. Data are presented as mean ±
SEM of three independent experiments.(carbamoylation) of the catalytic serine nucleophile (Alexander
and Cravatt, 2005; Bar-On et al., 2002) (Figure 1A). We therefore
sought to test whether this mechanism was operational for
inhibition ofMAGL by JZL184. JZL184-treated and dimethyl sulf-
oxide (DMSO)-treated (control) preparations of purified MAGL
were digested with trypsin and analyzed by liquid chromatog-
raphy tandemmass spectrometry (LC-MS/MS) on a high-resolu-
tion instrument (LTQ-Orbitrap). We searched the resulting MS1
(parent ion) profiles for masses corresponding to the unmodified
and carbamoylated forms of the MAGL active site peptide. In
control samples without inhibitor, we observed a single peak
with m/z = 1312.96, corresponding to the 4+ charge state of
the unmodified MAGL active site tryptic peptide, amino acids
110–160. In samples treated with JZL184, a new peak appeared
withm/z = 1408.24, corresponding to the 4+ charge state of the
carbamoylated form of the active site peptide (Figure 1B). The de-
tected adduct was unique to the active site peptide, because an
analysis of other tryptic peptides derived from MAGL revealed no
evidence of JZL184 adducts (see Figure S1 available online). MS/
MS analysis of the unmodified and JZL184-modified forms of the
active site peptide identified six common y1+ fragment ions (Fig-
ure 1C). Notably, the active site peptide contains three serine resi-
dues, and two of these serines are detected in unmodified form in
the y151+ and y161+ MS/MS fragment ions for both control and
JLZ184-treated MAGL preparations (Figure 1C). The remaining
serine, which is located in the portion of the active site peptide
modified by JZL184, corresponds to the predicted catalytic nucle-
ophile Ser122, based on previous studies (Karlsson et al., 1997)
and the complete conservation of this residue across all MAGL or-
thologs and distantly homologous serine hydrolases.We therefore
recombinantly expressedandpurifiedaMAGLmutant inwhich the
catalytic Ser122 was mutated to an alanine (MAGL-S122A). Upon
incubation with JZL184, digestion with trypsin, and LC-MS/MS
analysis, we detected a peak with m/z = 1308.96 correspondingChemistry & Biology 1to the 4+ charge state of the unmodified MAGL-S122A active site
tryptic peptide, but did not detect a peak corresponding to the
JZL184-adduct of this peptide (Figure S2). Collectively, these
data indicate that JZL184 inactivates MAGL by covalent carba-
moylation of the enzyme’s catalytic nucleophile Ser122.
To assess the stability of the JZL184-MAGL adduct, we mea-
sured the rate of decarbamoylation of this complex by incubating
recombinant MAGL overexpressed in COS7 cells with JZL184
and then using size-exclusion chromatography to remove
unreacted JZL184. MAGL activity was then measured by 2-AG
hydrolysis assays over a period of 30 hr at room temperature.
Less than 10% recovery of enzyme activity was observed over
this period (Figure 1D), indicating that the JZL184-MAGL adduct
is very stable.
An Optimized Vehicle Delivery System for In Vivo
Analysis of JZL184
In our initial disclosure of JZL184, we administered the
compound intraperitoneally (i.p.) to mice in a polyethylene glycol
(PEG) vehicle (Long et al., 2009) because this vehicle best solu-
bilized JZL184 (Figure S3). However, we have found that the PEG
vehicle can confound certain metabolomic measurements,
especially in peripheral tissues where PEG can accumulate
and reside for extended periods. Owing to the popularity of
saline-emulphor vehicles for delivering inhibitors and other phar-
macological agents (Fegley et al., 2005; Lichtman et al., 2001;
Verty et al., 2003), we explored the possibility of administering
JZL184 in an 18:1:1 solution of saline:emulphor:ethanol. Simple
addition of JZL184 to this vehicle resulted in poor solubility and
in vivo activity (as judged by lack of MAGL inhibition in brain
tissue; data not shown). However, extensive sonication of
JZL184 in the saline-emulphor vehicle produced a uniform
suspension (Figure S3) that could be administered to rodents
by intraperitoneal injection to efficiently inactivate MAGL in vivo.6, 744–753, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 745
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MAGL Function in Endocannabinoid MetabolismFigure 2. Comparison of Vehicles for
JZL184 Administration to Mice
(A, B) Serine hydrolase activity profiles as deter-
mined by reactivity with the ABPP probe FP-
rhodamine (A, fluorescent gel shown in grayscale)
and 2-AG and AEA hydrolysis activity assays (B) of
brain membranes prepared frommice treated with
JZL184 (saline-emulphor, i.p., 4–40 mg kg1, 4 hr).
(C) Total brain 2-AG, PG (C16:0), OG (C18:1), and
AEA measurements from mice treated with
JZL184 (4–40 mg kg1) in the indicated vehicle
for 4 hr.
(D–I). Locomotor activity (D, G), thermal pain
sensation (E, H), and rectal temperature (F, I) of
mice treated with JZL184 in the PEG (16 mg
kg1, i.p., 4 hr; upper panels) or saline-emulphor
(40 mg kg1, i.p., 4 hr; lower panels) vehicle.
Mice in either treatment group were not cataleptic.
Administration of the CB1 antagonist rimonabant
(RIM, i.p., 3 mg kg1) to mice 15 min before
JZL184 treatment blocked the observed behav-
ioral effects in the saline-emulphor group (D–F,
lower panels). RIM has previously been shown to
block the behavioral effects of JZL184 adminis-
tered in the PEG vehicle (Long et al., 2009). *p <
0.05, **p < 0.01, ***p < 0.001 for inhibitor-treated
versus vehicle-treated animals; ### p < 0.001 for
RIM- and inhibitor-treated versus inhibitor-treated
animals.
Data are presented as mean ± SEM. For B and C,
n = 3–6/group; for D–F, n = 10–18/group.We directly compared the PEG and saline-emulphor delivery
systems for JZL184 by measuring brain MAGL activity and lipid
levels from inhibitor-treated mice. C57Bl/6 mice were treated
with JZL184 (4–40 mg kg1, 18:1:1 saline:ethanol:emulphor
vehicle, i.p. or 16 mg kg1, PEG vehicle, i.p.) and killed after 4 hr
for analysis. JZL184 in both vehicles produced near-complete
andselectiveblockadeofMAGLactivity as judgedbycompetitive
ABPP with the serine hydrolase-directed probe fluorophospho-
nate (FP)-rhodamine (Patricelli et al., 2001) (Figure 2A) or 2-AG
hydrolytic substrate assays (Figure 2B), whichwas accompanied
by dramatic elevations in 2-AG (Figure 2C, left panel) and more
modest changes in other MAGs such as mono-palmitoylglycerol
(C16:0 MAG) and mono-oleoylglycerol (C18:1 MAG) (Figure 2C,
middle panel). A slightly higher dose of JZL184 was required in
the saline-emulphor vehicle to achieve the same 2-AG elevations
as observedwith thePEGvehicle (40mgkg1 versus 16mgkg1,
respectively; Figure 2C, left panel). JZL184 showed excellent
selectivity in thenervoussystem,because thisagentdidnotblock
FP-rhodamine labeling of other brain hydrolases (Figure 2A) and
showed only modest inhibition of FAAH activity (50% at the
highest dose tested, Figure 2B) that did not produce changes in
brain AEA levels (Figure 2C, right panel). These observations are
consistent with previous reports that >85% FAAH inhibition is
required to observe bulk (Ahn et al., 2009; Fegley et al., 2005) or
stimulated (Longet al., 2009) changes inAEA levels in the nervous
system. 2-AGwas similarly elevated in FAAH (/) mice (Cravatt
et al., 2001) treated with JZL184 (Figure S4), demonstrating that
genetic disruption of FAAH does not alter brain 2-AGmetabolism
by MAGL.
Consistent with our previous report (Long et al., 2009), JZL184
administered in a PEG vehicle was found to cause three of the746 Chemistry & Biology 16, 744–753, July 31, 2009 ª2009 Elsevierfour behavioral effects of the tetrad test characteristic of direct
CB1 agonists, namely, hypomotility (Figure 2D), analgesia (Fig-
ure 2E), and hypothermia (Figure 2F), but not catalepsy. Interest-
ingly, a slightly different profile was observed for JZL184 in the
saline-emulphor vehicle (40 mg kg1, i.p., 4 hr), where we
observed significant CB1-dependent hypomotility (Figure 2G)
and analgesia (Figure 2H), but not hypothermia (Figure 2I). The
discrepancy in the hypothermic effects of JZL184 administered
in different vehicles might be explained in part by the fact that
the PEG vehicle alone (but not the saline-emulphor vehicle)
caused a transient drop in body temperature, which might
suggest that blockade ofMAGL causes dysregulation of temper-
ature homeostasis following a hypothermic insult.
Evaluating the Inhibition of MAGL in Liver by JZL184
We next set out to assess the ability of JZL184 to inhibit MAGL
outside of the nervous system. C57Bl/6 mice were treated
with JZL184 (16 mg kg1 in saline-emulphor, i.p.), killed 15 min,
45 min, 2 hr, or 4 hr after treatment, and liver tissues removed
for analysis. MAGL inactivation in liver, as judged by 2-AG hydro-
lysis or competitive ABPP assays, was extremely rapid, reaching
near completion by the first time point analyzed (15 min,
Figure 3A). We observed a residual 20% 2-AG hydrolytic activity
that was insensitive to JZL184 (Figure 3B), indicating that, like in
brain (Blankmanetal., 2007;Longetal., 2009), additional enzymes
in liver might catalyze this reaction. In contrast to the rapid inacti-
vationofMAGLbyJZL184,FAAHwas inhibitedmuchmoreslowly,
with 50% FAAH activity still observed at 4 hr after treatment
(Figure 3B). Lipid profiles revealed significant elevations in 2-AG
and C16:0 and C18:1 MAGs in liver tissue from JZL184-treated
mice that peaked between 2 and 4 hr after inhibitor treatment.Ltd All rights reserved
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MAGL Function in Endocannabinoid MetabolismFigure 3. Time Course and Dose-Response
Analysis of MAGL Inactivation by JZL184
in Liver
(A and B) Serine hydrolase activity profiles as
judged by FP-rhodamine labeling (A) and 2-AG
and AEA hydrolysis assays (B) of liver membranes
from mice treated with JZL184 (16 mg kg1 in
saline-emulphor, i.p.) for the indicated times.
(C) Liver 2-AG (C20:4), PG (C16:0), OG (C18:1),
and AEA levels from mice treated with JZL184
(16 mg kg1 in saline-emulphor, i.p.) for the indi-
cated times.
(D and E) Serine hydrolase activity profiles (D) and
2-AG and AEA hydrolysis assays (E) of liver
membranes from mice treated with JZL184 at
the indicated doses (4–40 mg kg1, i.p., 4 hr).
(F) Liver 2-AG (C20:4), PG (C16:0), OG (C18:1), and
AEA levels from mice treated with JZL184 at the
indicated doses (4–40 mg kg1 in saline-emul-
phor, i.p., 4 hr). *p < 0.05, **p < 0.01 for inhibitor-
treated versus vehicle-treated animals. Data are
presented as mean ± SEM; n = 3–4/group.
(A and D) Lower gels show higher intensity of
imagoes of the MAGL signals.No changes in AEA levels were detected in liver at any time point
after JZL184 treatment (Figure 3C). C57Bl/6 mice treated with
increasing amounts of JZL184 (4–40 mg kg1, i.p., saline-emul-
phor, 4 hr) showed dose-dependent decreases in MAGL activity
by competitive ABPP (Figure 3D) and substrate hydrolysis assays
(Figure 3E) that correlatedwith dose-dependent elevations in liver
MAGs (Figure 3F). No change in liver AEA was observed at any of
the doses tested (p > 0.20) (Figure 3F).
Competitive ABPP experiments revealed that JZL184 main-
tained excellent selectivity for MAGL in liver tissue, especially
at early time points (<45 min, 16 mg kg1) (Figure 3A). At longer
time points (4 hr; Figure 3A) or higher doses (40 mg kg1;
Figure 3D), we observed a partial decrease in probe labeling
signals for multiple proteins in the 50–65 kDa region, which likely
correspond to carboxylesterases that are known to be sensitive
to a variety of carbamate-based inhibitors (Ahn et al., 2007; Alex-
ander and Cravatt, 2005; Zhang et al., 2007).
A Comprehensive Profile of MAGL Inactivation
in Peripheral Tissues
The heightened magnitude of accumulation of 2-AG in brain
versus liver tissue from JZL184-treated animals suggested that
the former tissue exhibits greater capacity to produce this endo-
cannabinoid. To better understand the relative level of
endocannabinoid tone across different tissues, we evaluated
MAGL activity and lipid profiles in brain, liver, kidney, spleen,
heart, testis, lung, and white (WAT) and brown (BAT) adipose
tissue from vehicle- and JZL184-treated mice. C57Bl/6 mice
were treated with JZL184 at 16 mg kg1 in saline-emulphor,
killed at 2 hr, and their tissues were harvested. We detected a
33 kDa, JZL184-sensitive band by gel-based ABPP in every
tissue proteome analyzed (Figures 4A–4I). In brain and testis,
a 35 kDa form of MAGL was also observed by gel-based
ABPP, as reported previously (Blankman et al., 2007; Long
et al., 2009), perhaps reflecting an additional splice isoform ofChemistry & Biology 1MAGL in these tissues (Karlsson et al., 2001). Despite producing
an equivalent and near-complete blockade of MAGL activity
in each tissue (as judged by FP-rhodamine labeling), JZL184
inhibited 2-AG hydrolysis activity in these tissues to varying
extents. For most tissues, a >50% block of 2-AG hydrolysis
activity was observed in JZL184-treated animals (Figure 4).
BAT and WAT, however, showed only modest 30% decreases
in activity (Figures 4F and 4G), possibly reflecting the action of
other 2-AG hydrolases in these fat tissues, such as hormone-
sensitive lipase, that are insensitive to JZL184.
Individual tissues showed markedly different extents and
patterns of MAG accumulation following MAGL inhibition by
JZL184. As reported previously, brain exhibited a dramatic
(>5-fold) increase in 2-AG levels, but more modest (2-fold)
increases in C16:0 and C18:1MAGs. Liver, kidney, spleen, heart,
andBATshowedsignificant (p < 0.05) elevations across the entire
panel of MAG species analyzed, with the largest elevations being
observed in the C16:0 and C18:1 species (Figures 4B–4F). WAT
and lung, however, did not show elevations in 2-AG, but accumu-
lated both C16:0 and C18:1 MAG (Figures 4G and 4H). Finally,
despite the presence of MAGL in testis and its inactivation by
JZL184 as judged by ABPP and 2-AG hydrolysis assays, we did
notobserveanysignificant changes (p>0.05) in anyMAGspecies
in this tissue (Figure 4I). We also did not observe any significant
accumulation (p > 0.05) of AEA in any of the tissues in this analysis
(Figures 4A–4I). Lastly, we confirmed that JZL184 reducedarach-
idonic acid levels in brain (Table S1) as had been previously
reported (Long et al., 2009; Nomura et al., 2008b), but found no
changes in palmitic, stearic, oleic, or arachidonic acid levels in
any of the peripheral tissues analyzed (Figure S5).
Selectivity Profiling of JZL184 in Peripheral Mouse
Tissues
The pharmacological value of JZL184 for characterizing the physi-
ological functions of MAGL depends on the selectivity of this6, 744–753, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 747
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MAGL Function in Endocannabinoid MetabolismFigure 4. A Comprehensive Biochemical Profile of MAGL Inactivation in Tissues for JZL184-Treated Mice
(A–I) Serine hydrolase activity profiles as judged by FP-rhodamine labeling, 2-AG hydrolysis activity, and levels of MAGs and AEA in brain (A), liver (B), kidney (C),
spleen (D), heart (E), brown adipose tissue (BAT) (F), white adipose tissue (WAT) (G), lung (H), and testis (I) from mice treated with JZL184 (16 mg kg1 in saline-
emulphor, i.p., 2 hr). JZL184 off-targets are indicated by arrowheads. The 2 hr metabolic data from liver is from the time course analysis presented in Figure 3C.
*p < 0.05, **p < 0.01, ***p < 0.001 for inhibitor-treated versus vehicle-treated animals. Data are presented as mean ± SEM; n = 4–6/group.748 Chemistry & Biology 16, 744–753, July 31, 2009 ª2009 Elsevier Ltd All rights reserved
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MAGL Function in Endocannabinoid Metabolisminhibitor. Of the nine tissues analyzed by competitive ABPP from
JZL184-treated mice, only spleen and lung contained detectable
off-target(s), which migrated between 60 and 75 kDa. To further
characterize these peripheral off-targets of JZL184, we analyzed
lung membrane proteomes using an advanced LC-MS platform,
termed ABPP-MudPIT, that displays enhanced resolution and
sensitivity compared with gel-based ABPP (Jessani et al., 2005).
Briefly, lung membrane proteomes frommice treated with JZL184
or vehicleweresubjected tocompetitiveABPPwith thebiotinylated
fluorophosphonate (FP) probe, FP-biotin (Liu et al., 1999). FP-
biotin-labeled proteins were then enriched with avidin, digested
on-bead with trypsin, analyzed by multidimensional LC-MS, and
identified and quantified using the SEQUEST search algorithm
(Eng et al., 1994) and spectral counting (Liu et al., 2004), respec-
tively. ABPP-MudPIT confirmed that JZL184 (16 mg kg1 in
saline-emulphor, i.p., 2 hr) completely inhibited MAGL in lung
membrane proteomes and also identified three additional targets
of this compound, all from the carboxylesterase family: esterase 1
(ES1), esterase1-like (ES1L), andcarboxylesteraseML1 (alsoanno-
tated as a second triglyceride hydrolase, TGH2 [Okazaki et al.,
2006]) (Figure 5 and Table S2). The spectral count signals for
hormone-sensitive lipase (HSL) were also lower in JZL184-treated
lung proteomes, although this reduction did not reach statistical
significance. To confirmwhether these enzymeswere valid targets
of JZL184, we recombinantly expressed ES1, TGH2, and HSL in
COS7cellsandevaluated themforsensitivity toJZL184bycompet-
itive ABPP. JZL184 inhibited FP-rhodamine labeling of both ES1
and TGH2 (Figure 5) with potencies comparable to the inhibition
of recombinant mouse MAGL (Long et al., 2009; Nomura et al.,
2008b). In contrast, FP-rhodamine labeling of recombinant HSL
was not impaired (Figure 5), confirming that this hydrolase is not
a target of JZL184. Collectively, these functional proteomic data
indicate that JZL184 maintains excellent selectivity for MAGL
acrossmostmouse tissues, targetingonly a limitednumberof addi-
tional hydrolases in a subset of peripheral tissues.
JZL184 Is Equipotent against Human and Mouse MAGL,
but Less Active against Rat MAGL
To understand the scope of JZL184 activity against different
MAGL orthologs, we recombinantly expressed mouse, rat, and
Figure 5. ABPP-MudPIT Analysis of Lung
Membrane Proteomes from Mice Treated
with JZL184 (16 mg kg1, i.p., 2 hr)
(Insert) Competitive ABPP measuring JZL184
blockade of FP-rhodamine for ES1, TGH2, and
HSL recombinantly expressed in COS7 cells (left
insert, representative competitive ABPP gels; right
insert, quantification of blockade of FP-rhodamine
labeling). Data are presented as mean ± SEM of
three independent experiments. *p < 0.05, **p <
0.01, for inhibitor-treated versus vehicle-treated
animals.
human MAGL in COS7 cells and
measured JZL184 inactivation of these
enzymes in vitro by substrate assays
(Figure 6A). JZL184 inhibited mouse and
human MAGL with equal potency, but
showed 10-fold lower activity against rat MAGL (Figure 6B).
We confirmed the lower potency of JZL184 against rat MAGL
by in vitro competitive ABPP analysis of mouse and rat brain
membranes (Figures 6C and 6D). JZL184 also appears to
show a similar reduction in activity against rat FAAH, resulting
in an overall similar relative selectivity windows for MAGL over
FAAH in both mouse and rat brain proteomes (Figure 6D). Lastly,
JZL184 showed equivalent potency against rat and mouse
ABHD6 (Figure 6D), a second 2-AG hydrolase expressed in brain
(Blankman et al., 2007).
DISCUSSION
Despite its molecular characterization over a decade ago (Karls-
son et al., 1997), the physiological functions of MAGL have re-
mained relatively enigmatic due to a dearth of pharmacological
tools or genetic models to test the enzyme’s function in vivo.
We recently introduced an efficacious and selective inhibitor of
MAGL, termed JZL184, and showed that this agent can selec-
tively block MAGL activity in the nervous system of mice (Long
et al., 2009; Nomura et al., 2008b). However, the mechanism
by which JZL184 inhibits MAGL, as well as the scope of its inhib-
itory effect on MAGL in various tissues, remained unknown.
Here, we provide clear evidence that JZL184 acts as a long-
lasting irreversible inhibitor of MAGL by carbamoylating the
enzyme’s serine nucleophile. We furthermore show that
JZL184 inactivates MAGL with good efficacy and selectivity in
a wide range of central and peripheral tissues.
Interestingly, the impact of MAGL blockade on endocannabi-
noid/MAG metabolism differed markedly in individual tissues. In
brain, both the basal level of 2-AG (5–10 nmol/g) and its fold-
elevation following MAGL inhibition (>5-fold) were much higher
than in any peripheral tissue (Figure 4A). In contrast, several
peripheral tissues from JZL184-treated mice accumulated
substantial quantities of C16:0 andC18:1MAGs (the two species
that were only modestly elevated in brain), while showing little or
no elevation in 2-AG (Figure 4). These data, in addition to the high
relative expression of CB1 in the brain compared with peripheral
tissues (Mackie, 2005), might suggest enhanced tonic levels of
2-AGmetabolism and signaling in the nervous system comparedChemistry & Biology 16, 744–753, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 749
Chemistry & Biology
MAGL Function in Endocannabinoid Metabolismwith peripheral tissues. Conversely, the more dramatic eleva-
tions in C16:0 and C18:1 MAGs observed in some peripheral
tissues following MAGL blockade might reflect a more general
metabolic function for this enzyme at these sites. Another feature
distinctive to MAGL in the nervous system is its regulation of
brain arachidonic acid levels (Table S1), which was not observed
in any peripheral tissues (Figure S5). These data again under-
score differences in the function of MAGL in the brain and the
periphery.
Because all tissues analyzed from JZL184-treated mice
showed >90% inhibition of MAGL as judged by gel-based
ABPP (Figure 4), we presume that the distinct MAG profiles
observed in individual tissues upon JZL184 treatment arise
fromother factors suchas thepresenceof additionalMAGhydro-
lases or different capacities for MAG biosynthesis. The former
possibility seems likely in organs, such as WAT, where other
enzymes that display MAG hydrolytic activity, such as HSL, are
present at high levels (Fredrikson and Belfrage, 1983; Osuga
et al., 2000). The latter possibility is supported by preliminary
time-course experiments, which have revealed similar relative
rates of 2-AG accumulation in the brain and liver upon JZL184
treatment, but distinct plateau values for elevations in this endo-
cannabinoid (11- and 4-fold, respectively) (Figure S5). Regard-
less of the precise mechanism, tissue-specific differences in
endocannabinoid metabolism might help to explain the diversity
of physiological functions performed by this lipid signaling
system. Indeed, recent evidence suggests that CB1 antagonists
affect metabolism, at least in part, by disrupting endocannabi-
noid pathways at peripheral sites such as liver (Osei-Hyiaman
et al., 2008) and adipocytes (Motaghedi and McGraw, 2008).
Figure 6. Characterization of JZL184 Inhibi-
tion of Mouse, Rat, and Human MAGL
(A) FP-rhodamine labeling of recombinant mouse,
rat, and human MAGL expressed in COS7 cells
(1 mM FP-rhodamine, 30 min).
(B) Blockade of recombinant MAGL orthologs by
JZL184 as determined by substrate assays with
2-AG. Data are presented as mean ± SEM of three
independent experiments.
(C and D) Competitive ABPP showing the effect of
JZL184 on serine hydrolase activities in the mouse
(C) and rat (D) brain membrane proteomes.
For B–D, JZL184 was incubated with cell/tissue
lysates (30 min, 37C) at the indicated concentra-
tions, followed by addition of 2-AG (100 mM, 5min,
room temperature) (B) or FP-rhodamine (1 mM,
30 min, room temperature) (C and D). For C and
D, control proteomes were treated with DMSO
alone. Note that mouse and rat brain MAGL
migrates as a 33 and 35 kDa doublet by SDS-
PAGE, as reported previously (Blankman et al.,
2007; Long et al., 2009).
Determining how the local concentrations
of endocannabinoids are regulated at
these peripheral sites is critical to achieve
a full understanding of the mechanism of
action of these signaling lipids.
Our studies also point to two areas for
future improvement of MAGL inhibitors.
First, although competitive ABPP confirmed that JZL184 gener-
ally displays high selectivity for MAGL, a handful of additional
targets were discovered in select peripheral tissues. That these
‘‘off-targets’’ corresponded to carboxylesterases is not sur-
prising, given that other carbamates, such as the FAAH inhibitor
URB597, have also been shown to inhibit carboxylesterases
(Alexander and Cravatt, 2005; Zhang et al., 2007). Although we
have previously demonstrated that JZL184 does not interact
with other components of the endocannabinoid system (Long
et al., 2009), we cannot exclude the possibility that JZL184 inter-
acts with other proteins outside of the serine hydrolase super-
family, such as cytochrome P450 enzymes, that might also
participate in lipid metabolism (Chen et al., 2008). Although the
inhibition of carboxylesterases and other potential off-targets
could complicate interpretation of JZL184’s pharmacological
effects in certain peripheral tissues, assessing the reversibility
of observed effects by cannabinoid receptor antagonists should
clarify whether they are due to the enhanced 2-AG signaling or
a different mechanism. Regardless, having defined the principal
off-targets of JZL184 through functional proteomic profiling, we
are in good position to move forward with directed medicinal
chemistry efforts to improve the selectivity of this inhibitor. A
second feature of JZL184 to consider for future refinement is
species selectivity. JZL184 potently inhibited both mouse and
human MAGL, but showed a 10-fold reduced activity against
rat MAGL. Because rats are extensively used as a model system
for studying higher-order behaviors, it would be beneficial to
develop inhibitors with improved activity against rat MAGL.
However, this task might prove difficult to accomplish using
the piperidine carbamate scaffold of JZL184, because our750 Chemistry & Biology 16, 744–753, July 31, 2009 ª2009 Elsevier Ltd All rights reserved
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vealed a consistent trend toward higher potency for mouse
and human MAGL over rat MAGL (our unpublished observa-
tions). Considering the high sequence identity shared by the
three MAGL orthologs (92% between mouse and rat MAGL
and 84% between mouse and human MAGL), we anticipate
that structural studies might be required to clarify their surprising
differences in sensitivity to JZL184 and related compounds.
SIGNIFICANCE
Monoacylglycerol lipase (MAGL) is a principal degradative
enzyme for the endocannabinoid 2-arachidonoylglycerol
(2-AG). Selective inhibitors of MAGL are therefore of value
as both research tools to study the physiological functions
of the endocannabinoid system and potential pharmaceu-
tical agents to perturb this system for therapeutic gain.
Here, we have shown that the piperidine carbamate JZL184
irreversibly inactivates MAGL by carbamoylation of the
enzyme’s catalytic serine nucleophile. This inhibition is
observed in vivo with high selectivity in both central and
peripheral tissues, enabling a comprehensive analysis of
the contribution that MAGL makes to the metabolism of
2-AG and other monoglycerides. Interestingly, our studies
provide evidence for marked tissue-specific differences in
endocannabinoid tone, with brain showing the most
dramatic elevations in 2-AG following MAGL blockade. In
contrast, MAGL’s control over the levels of 2-AG and other
monoglycerides varied considerably in peripheral tissues,
even in cases where this enzyme was largely responsible
for bulk 2-AG hydrolytic activity. These data thus point to
organs where MAGL-regulated 2-AG signaling might have
its most profound effects on physiology and, conversely, to
tissues where other enzymes might contribute to 2-AG and
monoglyceride metabolism in vivo.
EXPERIMENTAL PROCEDURES
Materials
2-AG, d5-2-AG, AEA, d4-AEA, d4-PEA, and pentadecanoic acid were
purchased from Cayman Chemicals. Monopentadecanoin andmonoheptade-
canoin were purchased from Nu-Chek-Prep, Inc. FP-rhodamine (Patricelli
et al., 2001), FP-biotin (Liu et al., 1999), and JZL184 (Long et al., 2009) were
synthesized as described previously.
Expression and Purification of Recombinant
MAGL and MAGL-S122A
Human MAGL was polymerase chain reaction (PCR) amplified using the
following primers: forward, GACTGGATCCCATGCCAGAGGAAAGTTC; re-
verse, CAGTAAGCTTTCAGGGTGGGGACGCAGTTC. The PCR product was
subsequently cloned into pET-45b(+) (Novagen) using BamHI and HindIII
restriction sites. The resulting hMAGL-pET45b(+) construct was transformed
into BL21(DE3) cells (Invitrogen) for expression. A single colony from a fresh
transformation was used to inoculate an overnight culture in a media of LB
containing 100 mg ml1 carbenicillin (LBcarb), incubated at 37C with shaking
(225 rpm). The following morning, the overnight culture was used to seed
the induction culture at a ratio of 1:100. The induction culture was incubated
at 37C with shaking (225 rpm) and the OD600 was monitored each hour.
Once the OD600 reached 0.4–0.6 1mM IPTGwas added each induction culture
and allowed to incubate for additional 4 hr. Cells were harvested by centrifu-
gation at 6000 x g for 10min at 4C. Cell pellets were stored at80C. To purify
6xHIS-hMAGL, cell pellets from a 1 l culture were thawed at room temperatureChemistry & Biology 16in a buffer containing 50 mM Tris (pH 8.0), 200 mM NaCl, 1% LDAO, lysozyme
(0.25 mg ml1), and DNase I (25 mg ml1) with constant stirring for 10 min,
after which cells were lysed by sonication. The soluble and insoluble materials
were separated by centrifugation at 24,000 x g for 30 min at 4C. The resulting
supernatant was batch loaded with 0.5 ml TALON Metal Affinity Resin (Clon-
tech) (50% slurry) for 1 hr at 4C. The loaded resin was added to a column
and washed with 10 column volumes (CV) of 50 mM Tris (pH 8.0), 200 mM
NaCl (wash buffer), 10 CV wash buffer containing 5 mM imidazole, 10 CV of
wash buffer containing 10 mM imidazole, and eluted with wash buffer contain-
ing with 200mM imidazole. The eluted protein was subsequently concentrated
using an Amicon Ultra centrifugal filter device (Millipore) with 10,000 molecular
weight cut-off and the protein concentration determined using DC Protein
Assay (Bio-Rad). A typical 1 l pellet (1.5 g) will yield 1.5 mg MAGL of single
band purity when analyzed by SDS-PAGE and stained with Coomassie blue.
TheMAGL-S122A construct was created using the following primers: sense,
CTTCTGGGCCACGCCATGGGAGGCG; antisense, CGCCTCCCATGGCGTG
GCCCAGAAG, and the Stratagene QuikChange II Site-Directed Mutagenesis
kit according to the manufacturer’s protocols.
LC-MS/MS Detection of Modified and Unmodified Tryptic Peptides
from JZL184-Treated Preparations of MAGL
Purified, recombinant hMAGL (50 ml, 5 mg ml1) was incubated with DMSO
(1 ml) or JZL184 (1 ml, 200 mM final) for 20 min at room temperature. Urea
(100mg) was added to each reaction and the reactionswere dilutedwith phos-
phate-buffered saline (PBS, 150 ml). Each sample was then subsequently incu-
bated with tris-(2-carboxyethyl)phosphine (TCEP, 5 mM) and iodoacetamide
(10 mM) for 30 min each at room temperature. The samples were diluted again
with ammonium bicarbonate (25 mM, 550 ml) and subjected to trypsin diges-
tion overnight at 37C. The next day, samples were concentrated, resus-
pended in ammonium bicarbonate (25 mM, 200 ml) with 0.1% formic acid,
and a 10 ml aliquot was pressure loaded onto a 100 mm (inner diameter) fused
silica capillary column with a 5 mm tip that contained 10 cm C18 resin (aqua
5 mm, Phenomenex). LC-MS/MS analysis was performed on an LTQ-Orbitrap
mass spectrometer (ThermoFisher) coupled to an Agilent 1100 series HPLC.
Peptides were eluted from the column using a 125 min gradient of 5%–
100% Buffer B (Buffer B: 20% water, 80% acetonitrile, 0.1% formic acid).
The flow rate through the column was 0.25 ml min1 and the spray voltage
was 2.5 kV. The LTQ was operated in data-dependent scanning mode, with
one full MS scan (400–1600 m/z) followed by seven MS/MS scans of the nth
most abundant ions with dynamic exclusion enabled.
Measurement of Reversibility of JZL184-MAGL Reaction
Recombinant mMAGL overexpressed in COS7 cells was diluted in Tris buffer
(50 mM [pH 8], 1 mg ml1 final concentration, 130 ml final volume) and incu-
bated with JZL184 (100 mM) or DMSO for 30 min at room temperature. The
samples were then subjected to a PD10 size exclusion column (GE Health-
care), concentrated to 200 ml, and incubated at room temperature. At the
indicated times, an aliquot of each sample was removed and substrate hydro-
lysis activity was determined exactly as described below.
Preparations of Mouse and Rat Tissue Proteomes
Tissues were Dounce-homogenized in PBS (pH 7.5), followed by a low-speed
spin (1400 x g, 5 min) to remove debris. The supernatant was then subjected to
centrifugation (64,000 x g, 45min) to provide the cytosolic fraction in the super-
natant and the membrane fraction as a pellet. The pellet was washed and
resuspended in PBS buffer by sonication. Total protein concentration in
each fraction was determined using a protein assay kit (Bio-Rad). Samples
were stored at 80C until use.
Competitive ABPP Experiments
Tissue proteomes were diluted to 1 mg ml1 in PBS and FP-rhodamine was
added at a final concentration of 1 mM in a 50 ml total reaction volume. After
30 min at 25C, the reactions were quenched with 4x SDS-PAGE loading
buffer, boiled for 5 min at 90C, subjected to SDS-PAGE, and visualized in-gel
using a flatbed fluorescence scanner (Hitachi). For experiments involving apre-
incubation with inhibitor, the reactions were prepared without FP-rhodamine.
JZL184 was added at the indicated concentration and incubated for 30 min at
37C. FP-rhodamine was then added and the reaction was carried out exactly, 744–753, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 751
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membrane proteome (0.5 ml, 1 mg ml1 in PBS) from the mice treated with
JZL184 or vehicle as described above was labeled with 5 mM FP-biotin for
2 hr at room temperature and prepared for ABPP-MudPIT analysis as
described previously (Jessani et al., 2005; Long et al., 2009), except that the
Lys-C digestion step was omitted. MudPIT analysis of eluted peptides was
carried out as previously described on a coupled Agilent 1100 LC-ThermoFin-
nigan LTQ-MS instrument. All data sets were searched against the mouse IPI
database using the SEQUEST search algorithm (Eng et al., 1994) and the
results were filtered and grouped with DTASELECT (Tabb et al., 2002).
Peptides with cross-correlation scores greater than 1.8 (+1), 2.5 (+2), 3.5
(+3) and delta CN scores greater than 0.08 were included in the spectral count-
ing analysis. Spectral counts are reported as the average of three samples with
the standard error of the mean (SEM).
Recombinant Expression of Enzymes in COS7 Cells
Enzymeswere recombinantly expressed in COS7 using a previously described
procedure (Blankman et al., 2007) as detailed in Supplemental Data.
Enzyme Activity Assays
MAGL and FAAH substrate hydrolysis assays were performed using previ-
ously described LC-MS assays (Blankman et al., 2007) as detailed in Supple-
mental Data.
In Vivo Studies with JZL184
JZL184 was prepared as a saline-emulphor emulsion by vortexing, sonicating,
and gently heating neat compound directly into an 18:1:1 v/v/v solution of
saline:ethanol:emulphor (4, 1.6, or 0.4 mg ml1 final concentration), or as a
homogeneous PEG solution by vortexing, sonicating, and gently heating
neat compound directly into PEG300 (Fluka) (4 mg ml1 final concentration).
Male C57Bl/6J mice (<6 months old, 20–28 g) were i.p. administered JZL184
or an 18:1:1 v/v/v saline:emulphor:ethanol vehicle at a volume of 10 ml g1
weight (40, 16, or 4 mg kg1 by the dilutions above) or a PEG vehicle at
a volume of 4 ml g1 weight (16 mg kg1 by the dilution above). All experiments
were performed with the saline-emulphor vehicle unless otherwise indicated.
After the indicated amount of time, mice were anesthetized with isoflurane
and killed by decapitation. Brains were removed, hemisected along the
midsagittal plane, and each half was then flash frozen in liquid N2. Two sepa-
rate portions (100 mg) of the other indicated tissues were also harvested and
flash frozen in liquid N2. One portion of each tissue was analyzed by gel-based
ABPP and the other portion was used for metabolite analysis. Animal experi-
ments were conducted in accordance with the guidelines of the Institutional
Animal Care and Use Committee of The Scripps Research Institute.
Measurement of Brain Lipids
Brain lipid measurements were determined using a slight modification from
a previously described procedure (Long et al., 2009) as detailed in Supple-
mental Data.
Mouse Behavioral Experiments
Locomotor activity was assessed in a Plexiglas cage (18 3 10 3 8.5 in) that
was marked by 7 cm 3 7 cm grids on the bottom of the cage. The number
of grids traversed by the hind limbs was counted for 5 min. Nociception was
then assessed in the tail immersion assay, where each mouse was hand-
held and 1 cm of the tail was submerged into a 56C water bath. The latency
for the mouse to withdrawal its tail was scored. Rectal temperature was
assessed by inserting a thermocouple probe 1.2 cm into the rectum and
temperature was determined using a telethermometer. Preinjection tail immer-
sion latency and rectal temperature were alsomeasured as a baseline for each
mouse.
SUPPLEMENTAL DATA
Supplemental Data include six figures, two tables, and Supplemental Methods
andcanbe foundwith thisarticleonlineathttp://www.cell.com/chemistry-biology/
supplemental/S1074-5521(09)00176-8.752 Chemistry & Biology 16, 744–753, July 31, 2009 ª2009 ElsevierACKNOWLEDGMENTS
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